Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Health Catalyst’s Role in Healthcare Analytics in APAC

The future of the healthcare industry is increasingly being shaped by data and analytics. That’s why, for this episode of Owning the Future of Healthcare by Health Catalyst, host Daniel Litwin was joined by Farhana Nakhooda, Health Catalyst Senior Vice President of Healthcare and Life Sciences for APAC, who shared her influential insights. In particular,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

The future of the healthcare industry is increasingly being shaped by data and analytics. That’s why, for this episode of Owning the Future of Healthcare by Health Catalyst, host Daniel Litwin was joined by Farhana Nakhooda, Health Catalyst Senior Vice President of Healthcare and Life Sciences for APAC, who shared her influential insights.

In particular, Nakhooda contributed to an in-depth discussion about the organization’s impact on the efficient and equitable use of data and analytics in the Asia-Pacific region, or APAC.

Because the region is so large, Nakhooda said it’s impossible to generalize about universal trends in the area. However, when viewed through the lens of developed and developing markets, some easier-to-identify groupings and trends emerge.

While developed markets are more prepared for analytics than their developing counterparts thanks to, in many cases, years of EMR use, that doesn’t mean the adoption of more robust analytics will be simple. For example, digitization varies greatly among even developed markets, which can lead to implementation challenges.

Among developing markets, work is still centralized around enabling data capture in the first place.

Even though these segments of the region are at different stages of preparedness and adoption, Nakhooda said they do have some things in common, such as a requirement to share data with their governments.

Health Catalyst is working to help the region increase understanding of data security and the structure around data sharing and governance, as well as to help increase data and analytics literacy in the region, which is shining a spotlight on the power of data in improving outcomes and more.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512